SEC Filing Summary: Rexahn Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on January 3, 2008. The report addresses a completed private sale of the company's common stock. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification of a corporate event rather than a financial performance report.
Material Changes
- Capital Raise: The company completed a private sale of shares of its common stock.
- Disclosure: Details regarding the transaction are contained in a press release attached as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or contingencies beyond the announcement of the share sale. No unusual items were disclosed in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 3, 2008) for the specific terms, price, and volume of the private share sale.
- Verify the total capital raised and the number of shares issued in the transaction.
- Confirm the identity of the investors participating in the private placement.
- Check subsequent filings for any dilution impact on existing shareholders.